This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Access to Medicines Movement | |
|---|---|
| Name | Access to Medicines Movement |
| Caption | International advocacy for pharmaceutical access |
| Formation | 1990s |
| Founder | Médecins Sans Frontières; World Health Organization collaborators |
| Type | Advocacy network |
| Headquarters | Global (networks in Geneva, New York City, London) |
| Area served | Low-income countries; middle-income countries |
| Focus | Pharmaceutical access; intellectual property; public health |
Access to Medicines Movement
The Access to Medicines Movement is an international advocacy network focused on improving public health by increasing availability, affordability, and appropriateness of medicines and vaccines for populations in Sub-Saharan Africa, South Asia, and other regions. Rooted in collaborations among Médecins Sans Frontières, World Health Organization, UNAIDS, and civil society groups such as Treatment Action Campaign and Oxfam, the movement engages with policymakers, pharmaceutical companies like GlaxoSmithKline and Pfizer, intergovernmental bodies such as the World Trade Organization, and funding agencies including the Global Fund and Gavi, the Vaccine Alliance. Its activities intersect with major events and agreements like the Doha Declaration on the TRIPS Agreement and Public Health and crises including the HIV/AIDS pandemic, the Ebola virus epidemic in West Africa, and the COVID-19 pandemic.
The movement emerged during the late 1990s amid activism around HIV/AIDS treatment access, with pivotal campaigns linked to Médecins Sans Frontières's "Campaign for Access to Essential Medicines", pressure on firms such as Novartis and Bristol-Myers Squibb, legal confrontations in cases like Eldridge v. Canada and policy shifts around the Doha Declaration on the TRIPS Agreement and Public Health. Early alliances included Treatment Action Campaign in South Africa, global health NGOs such as Oxfam and Health Action International, and academic centers like Harvard University and London School of Hygiene & Tropical Medicine. The 2000s saw expansion through funding mechanisms created by The Global Fund to Fight AIDS, Tuberculosis and Malaria and procurement innovations led by Unitaid and Clinton Health Access Initiative, while later crises—2014 West Africa Ebola epidemic and 2019–20 COVID-19 pandemic—reinvigorated debates at forums including World Health Assembly and UN General Assembly.
Core goals include increasing affordability via TRIPS flexibilities recognized in the Doha Declaration on the TRIPS Agreement and Public Health, promoting technology transfer advocated by World Health Organization reports, ensuring equitable distribution as argued by UNAIDS and UNICEF, and advancing transparency in pricing promoted by Open Society Foundations and MedsPal. Principles emphasize human rights frameworks cited in Universal Declaration of Human Rights discussions, adherence to World Health Organization essential medicines lists, and partnership models exemplified by Medicines Patent Pool and licensing deals involving ViiV Healthcare.
Prominent issues include patent barriers highlighted in disputes like Novartis AG v. Union of India, compulsory licensing episodes such as Thailand compulsory licensing of antiretrovirals 2006–2007, and generic competition campaigns involving manufacturers in India and Brazil. Campaigns targeted pharmaceutical pricing policies by GlaxoSmithKline and Sanofi; procurement transparency initiatives interfaced with Gavi, the Vaccine Alliance and PAHO Revolving Fund procurement models. Vaccine equity campaigns during COVID-19 pandemic engaged actors including AstraZeneca, Moderna, and mechanisms like COVAX.
Civil society actors include Médecins Sans Frontières, Oxfam, Treatment Action Campaign, Health Action International, and Medicines Sans Frontières Access Campaign affiliates. Institutional partners and funders comprise World Health Organization, Global Fund, Gavi, the Vaccine Alliance, Unitaid, and Bill & Melinda Gates Foundation (as a funder of market-shaping initiatives). Legal and technical intermediaries include Medicines Patent Pool, Clinton Health Access Initiative, and academic hubs at University of Cape Town and Harvard T.H. Chan School of Public Health.
The movement leverages legal tools such as compulsory licensing under TRIPS, voluntary licenses brokered by Medicines Patent Pool, patent oppositions pursued before offices like the Indian Patent Office, and patent law litigation exemplified by Novartis AG v. Union of India. International policy instruments include the Doha Declaration on the TRIPS Agreement and Public Health, WHO Model List of Essential Medicines, and procurement frameworks like Pooled Procurement used by PAHO. Financing and market interventions come via advance market commitments such as those piloted by Gavi and Wellcome Trust-informed prize funds.
Achievements cited include expanded access to antiretrovirals during the HIV/AIDS pandemic, lower prices through generic competition in markets influenced by India's pharmaceutical sector, and accelerated vaccine distribution mediated by COVAX partnerships. Criticisms involve tensions with intellectual property proponents represented by firms like PhRMA and states such as United States in trade negotiations, debates over sustainability raised by World Bank analysts, and concerns about donor influence from foundations like Bill & Melinda Gates Foundation. Scholars at London School of Economics and Yale University have critiqued market-shaping approaches for potential distortion of research incentives.
- HIV/AIDS treatment scale-up: collaborations between Clinton Health Access Initiative, UNAIDS, Médecins Sans Frontières, and generic producers in India reduced antiretroviral prices and expanded treatment in South Africa and Uganda. - 2006–2007 Thailand compulsory licenses: the Thai Ministry of Public Health issued licenses against patents held by Merck and Abbott Laboratories to secure antiviral access. - Ebola response: procurement and trial coordination with WHO, MSF, and vaccine developers including rVSV-ZEBOV partnerships with Merck accelerated countermeasure deployment in Guinea. - COVID-19 vaccine equity: disputes over waiving TRIPS obligations at the World Trade Organization and allocations through COVAX involved Moderna, Pfizer–BioNTech, and national initiatives including ACT-Accelerator.
Future work focuses on reforming global innovation systems advocated by Commission on Intellectual Property Rights, Innovation and Public Health-informed proposals, scaling technology transfer hubs like the WHO mRNA Vaccine Technology Transfer Hub in South Africa, addressing antimicrobial resistance with stakeholders such as UN Interagency Coordination Group on Antimicrobial Resistance, and negotiating equitable frameworks at the World Trade Organization and World Health Assembly. Challenges include geopolitical competition involving China and United States, funding volatility linked to multilateral donors, and balancing incentives for pharmaceutical R&D as debated in literature from National Academies of Sciences, Engineering, and Medicine and policy briefs from Chatham House.
Category:Global health